Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A novel combination of ceria nanoparticles and mesenchymal stem cell nanovesicles modified both inflammation and autoimmunity in a mouse model of arthritis.
Globally, rheumatic musculoskeletal diseases constitute the most common causes of disability, related morbidity and economic loss worldwide. A shortage of rheumatologists warrants education of primary care doctors in primary care rheumatology, public awareness initiatives and advocacy for rheumatic musculoskeletal health.
Using multi-omics analyses, researchers have identified two distinct immunological phenotypes of microscopic polyangiitis, which could inform prognosis and personalized treatment.
New findings support the use of targeted next-generation sequencing of NOD2 to reassess the diagnosis of juvenile idiopathic arthritis in patients with signs and symptoms suggestive of Blau syndrome.
Researchers have conducted a comprehensive single-cell analysis of synovial tissue in rheumatoid arthritis, providing insights into the heterogeneity of the disease and informing future treatment strategies.
New research shows that the amino acid l-arginine ameliorates arthritis and inhibits inflammatory bone loss by altering energy metabolism in osteoclasts.
Dual inhibition of glycolysis and glutaminolysis in fibroblast-like synoviocytes with a compound called c28MS shows promise in a mouse model of rheumatoid arthritis
Biosimilars have an important place in the treatment of rheumatic conditions. The non-inferiority of biosimilars to bio-originators is ensured, but full and effective clinical adoption of these agents nonetheless requires consideration of several important issues, including the need for shared decision-making and a potential nocebo effect.
Chromatin accessibility of an enhancer that regulates the expression of a disease-associated microRNA is affected in monocytes from patients with systemic lupus erythematosus, highlighting this enhancer as a potential therapeutic target.
New research shows that a recombinant antibody that binds type II collagen protects against the development of arthritis in mice by blocking neutrophil recruitment.
Since entering the clinic 25 years ago, biologic TNF inhibitors have transformed the outlook for people with rheumatoid arthritis and set the standard for all other targeted therapies. Despite changes to the therapeutic landscape, TNF inhibitors look set to remain an important treatment option for the foreseeable future.
In an observational study, SARS-CoV-2 antibody therapy used as pre-exposure prophylaxis reduced the incidence of COVID-19 in individuals with rheumatic diseases.
New research shows that the FGF10–FGFR1 axis is highly activated in lining fibroblast-like synoviocytes during relapsing rheumatoid arthritis and is a potential therapeutic target.
New research shows that deficiency of the sulfation-related SLC26A2 affects osteocyte formation, and that targeting downstream mediators can ameliorate SLC26A2-deficient osteoporosis.
A monoclonal antibody targeting a peptide that replicates the proinflammatory properties of IL-17 has shown potent activity and an acceptable profile of adverse effects in pre-clinical studies.
New findings suggest that liposome-mediated delivery of a specific microRNA inhibitor can restore anti-inflammatory macrophage polarization and reduce joint inflammation in mice.
Although inflammatory arthritis induced by immune-checkpoint inhibitors clinically resembles that of rheumatoid arthritis or psoriatic arthritis, research shows that it differs in its associated T cell response.